PL1853721T3 - Sposób określania wrażliwości na inhibitory CHK1 - Google Patents

Sposób określania wrażliwości na inhibitory CHK1

Info

Publication number
PL1853721T3
PL1853721T3 PL06709785T PL06709785T PL1853721T3 PL 1853721 T3 PL1853721 T3 PL 1853721T3 PL 06709785 T PL06709785 T PL 06709785T PL 06709785 T PL06709785 T PL 06709785T PL 1853721 T3 PL1853721 T3 PL 1853721T3
Authority
PL
Poland
Prior art keywords
chk1
patient
determining susceptibility
chk1 inhibitors
signal transduction
Prior art date
Application number
PL06709785T
Other languages
English (en)
Inventor
Sonya Zabludoff
Louise Bergeron
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL1853721T3 publication Critical patent/PL1853721T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL06709785T 2005-02-18 2006-02-16 Sposób określania wrażliwości na inhibitory CHK1 PL1853721T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65413105P 2005-02-18 2005-02-18
EP06709785A EP1853721B1 (en) 2005-02-18 2006-02-16 Method for determining responsiveness to chk1 inhibitors
PCT/GB2006/000548 WO2006087557A1 (en) 2005-02-18 2006-02-16 METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS

Publications (1)

Publication Number Publication Date
PL1853721T3 true PL1853721T3 (pl) 2010-08-31

Family

ID=36295309

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06709785T PL1853721T3 (pl) 2005-02-18 2006-02-16 Sposób określania wrażliwości na inhibitory CHK1

Country Status (23)

Country Link
US (1) US20080145358A1 (pl)
EP (1) EP1853721B1 (pl)
JP (1) JP2008530575A (pl)
KR (1) KR20070107034A (pl)
CN (1) CN101120096A (pl)
AT (1) ATE464395T1 (pl)
AU (1) AU2006215413B2 (pl)
BR (1) BRPI0607798A2 (pl)
CA (1) CA2598185A1 (pl)
CY (1) CY1110076T1 (pl)
DE (1) DE602006013604D1 (pl)
DK (1) DK1853721T3 (pl)
ES (1) ES2341796T3 (pl)
HR (1) HRP20100313T1 (pl)
IL (1) IL184873A0 (pl)
MX (1) MX2007010073A (pl)
NO (1) NO20074610L (pl)
NZ (1) NZ556718A (pl)
PL (1) PL1853721T3 (pl)
PT (1) PT1853721E (pl)
SI (1) SI1853721T1 (pl)
WO (1) WO2006087557A1 (pl)
ZA (1) ZA200706670B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2086580A2 (en) * 2006-11-21 2009-08-12 Merial Limited Prime boost canine leishmania vaccine
US8173366B2 (en) 2007-03-29 2012-05-08 University of Pittsburgh—of the Commonwealth System of Higher Education Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
US8263329B2 (en) 2007-03-29 2012-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
JP5436786B2 (ja) * 2008-03-06 2014-03-05 オリンパス株式会社 細胞周期計測方法
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
WO2016126616A1 (en) 2015-02-02 2016-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and kits for measuring and quantifying dna double-stranded breaks using gamma-h2ax and h2ax
KR20180126085A (ko) * 2016-05-05 2018-11-26 난토믹스, 엘엘씨 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor)
EP3499228A4 (en) * 2016-08-12 2020-04-15 Hitachi Chemical Company, Ltd. METHOD FOR DETECTING CIRCULATING TUMOR CELLS AND PRE-TREATMENT METHOD FOR DETECTING CIRCULATING TUMOR CELLS
KR20220054644A (ko) * 2019-09-03 2022-05-03 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 환자 상태를 결정하기 위한 방법 및 제제
CA3261094A1 (en) 2022-07-13 2024-01-18 Acrivon Therapeutics, Inc. METHODS AND SYSTEMS FOR TREATING A DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001161398A (ja) * 1999-12-06 2001-06-19 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素の活性測定方法およびタンパク質リン酸化酵素の活性測定キット
PL378372A1 (pl) * 2003-01-09 2006-04-03 Pfizer Inc. Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii
EP1613625A1 (en) * 2003-03-14 2006-01-11 AstraZeneca AB Novel fused triazolones and the uses thereof
JP4597976B2 (ja) * 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾iRNA剤
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
US20050207998A1 (en) * 2003-07-21 2005-09-22 Yaoping Lu Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
AU2004274013A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation

Also Published As

Publication number Publication date
EP1853721B1 (en) 2010-04-14
ZA200706670B (en) 2008-10-29
NO20074610L (no) 2007-11-14
DE602006013604D1 (de) 2010-05-27
BRPI0607798A2 (pt) 2010-06-22
NZ556718A (en) 2010-10-29
KR20070107034A (ko) 2007-11-06
HK1113059A1 (en) 2008-09-19
CY1110076T1 (el) 2015-01-14
DK1853721T3 (da) 2010-06-14
HRP20100313T1 (hr) 2010-07-31
ATE464395T1 (de) 2010-04-15
SI1853721T1 (sl) 2010-06-30
IL184873A0 (en) 2007-12-03
AU2006215413B2 (en) 2010-10-07
ES2341796T3 (es) 2010-06-28
EP1853721A1 (en) 2007-11-14
MX2007010073A (es) 2007-10-10
WO2006087557A1 (en) 2006-08-24
CN101120096A (zh) 2008-02-06
PT1853721E (pt) 2010-06-08
US20080145358A1 (en) 2008-06-19
AU2006215413A1 (en) 2006-08-24
JP2008530575A (ja) 2008-08-07
CA2598185A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
ZA200706670B (en) Method for determining responsiveness to CHK1 inhibitors
FR2855877B1 (fr) Determination precoce des resultats de tests
ATE438853T1 (de) Diagnostische testvorrichtung
EP2015757A4 (en) HYDROLYSERESISTENT, BOROYED THERAPEUTIC USES
BRPI0710123A2 (pt) Previsão de heterose e outros traços por análise de transcriptoma.
EP2114990A4 (en) ASSOCIATED GENES AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFECT OF EGFR TK INHIBITORS
EP1802766A4 (en) METHOD FOR A GLOBAL COOLING AND FIBRINOLYSIS TEST
EP1994172A4 (en) METHOD FOR THE DIAGNOSIS AND / OR PREDICTION OF THE DEVELOPMENT OF ALLERGIC DISEASE AND AGENTS FOR TREATMENT AND / OR PREVENTING THEREOF
FR13C0025I1 (fr) Combinaisons antitumorales contenant vegf-trap et du 5fu ou un de ses derives
DE602007010246D1 (de) Verfahren zur blutgerinnungsbestimmung
WO2003103481A3 (en) Methods for detecting b. anthracis infection
WO2008089123A3 (en) Methods for analysis of hedgehog pathway inhibitors
EP2035551A4 (en) METHOD FOR IDENTIFYING ACTIVE CANDIDATES FOR FAT MOBILIZATION
DE60306865D1 (de) Detektion von Vancomycin-resistenten Enterococcus-Subspezies
WO2005113797A3 (en) METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
EP1929044A4 (en) METHOD AND SAMPLE COMBINATIONS FOR MELANOMA DETECTION
WO2008060400A3 (en) Sirtuin polymorphisms and methods of use thereof
WO2010030857A3 (en) Egfr inhibitor therapy responsiveness
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
WO2007047335A3 (en) Methods for use with baff antagonists
FR2880426B1 (fr) Procede et dispositif pour la determination du point de fumee des hydrocarbures
EP2102393A4 (en) FOR PLATINATE COORDINATION COMPLEX-INDUCED OTOTOXICITY, PRE-DICTIVE POLYMORPHISMS
MX2009008788A (es) Poliformismos de serpine1 son predictivos de respuesta a administracion de proteina c activada y riesgo de muerte.
EP1851338A4 (en) MULTICOMPONENT INHIBITORS OF NUCLEIC ACID POLYMERASES
EP2232256A4 (en) PROCESS FOR CLEANING BIOCHOES AND ANALYSIS OF BOHRLOCH FLUIDES